JPH0455671B2 - - Google Patents
Info
- Publication number
- JPH0455671B2 JPH0455671B2 JP59191603A JP19160384A JPH0455671B2 JP H0455671 B2 JPH0455671 B2 JP H0455671B2 JP 59191603 A JP59191603 A JP 59191603A JP 19160384 A JP19160384 A JP 19160384A JP H0455671 B2 JPH0455671 B2 JP H0455671B2
- Authority
- JP
- Japan
- Prior art keywords
- culture
- genetically modified
- controlling
- promoter
- gal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000002253 acid Substances 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 239000013612 plasmid Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 9
- 241000588724 Escherichia coli Species 0.000 claims description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 239000000411 inducer Substances 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 2
- 235000016709 nutrition Nutrition 0.000 claims description 2
- 108700026220 vif Genes Proteins 0.000 claims description 2
- PLVPPLCLBIEYEA-WAYWQWQTSA-N (z)-3-(1h-indol-3-yl)prop-2-enoic acid Chemical group C1=CC=C2C(\C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-WAYWQWQTSA-N 0.000 claims 2
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 claims 2
- 108010005774 beta-Galactosidase Proteins 0.000 description 20
- WQZGKKKJIJFFOK-FPRJBGLDSA-N beta-D-galactose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-FPRJBGLDSA-N 0.000 description 16
- 150000007513 acids Chemical class 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 230000001580 bacterial effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000005273 aeration Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 108010037870 Anthranilate Synthase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 101100408135 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) phnA gene Proteins 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 101150044170 trpE gene Proteins 0.000 description 1
- 101150108727 trpl gene Proteins 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/52—Improvements relating to the production of bulk chemicals using catalysts, e.g. selective catalysts
Landscapes
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Enzymes And Modification Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
〔発明の利用分野〕
本発明は動物、植物及び微生物等から得た目的
遺伝子を導入した微生物を効率よく培養し、目的
遺伝子産物を大量に生産する方法に関するもので
ある。
〔発明の背景〕
ある種の複合プラスミドは、培養中に誘導物質
を添加することにより遺伝子が発現することが知
られている。たとえば「Nature」vol.291、503
〜506頁、11June1981参照。
最近、宿主微生物のベクタープラスミドに有用
物質の生産情報を有する遺伝子を組込んだ複合プ
ラスミドを保持する宿主微生物を用いて、該微生
物に上記有用物質を大量生産させる遺伝子組換え
技術が発展してきた。この技術により既にヒトイ
ンターフエロンやインスリン等が生産されつつあ
り、大腸菌は宿主微生物として利用されている。
しかし、目的遺伝子を保持する遺伝子組換え菌
を用いて目的の生産物を大量に工業生産する方法
はまだ開発されておらず、遺伝子組換え菌の効率
的な培養方法の開発が急がれている。
〔発明の目的〕
本発明の目的は、遺伝子組換え菌の効率的な培
養方法を提供することにある。
〔発明の概要〕
本発明は、目的遺伝子、ベクター及びプロモー
タから成る複合プラスミドを細胞内に保持し、か
つ目的遺伝子の発現能を有する微生物を培養し、
目的遺伝子を発現させその生産物を採取するに際
し、培養中の溶存酸素(DO)濃度変化を指標と
し、誘導物質と栄養物質を同時に添加することに
ある。
本発明では培養制御方法を示す具体例として、
プロモータにtrpプロモータを用い、それにβ−
gal(β−ガラクトシダーゼ)遺伝子を連結した複
合プラスミドを保持する大腸菌による培養制御方
法を示す。
trpプロモータとβ−gal遺伝子を連結した複合
プラスミドpTREZ1の構造を第1図に示す。trp
プロモータ部分は大腸菌のtrpオペロンのプロモ
ータ、trpL(ソーダペプタイド)及びtrpE(アン
トラニル酸合成酵素)の先端部分の一部を含む約
500bp(base pairs、塩基対)のDNA断片であり、
pBR322プラスミドのEcoRI部位に挿入したもの
である。
一方、β−gal遺伝子はpMC1403(J.Ba−
cteriol.vol.143、971〜980頁、1980)より切り出
した6.2kbの大きさのもので、trpプロモータの
EcoRI部位とpBR322のSalI部位間に挿入した。
以上述べた構造の複合プラスミドpTREZ1を染
色体上のβ−gal遺伝子欠損株である大腸菌M182
株に導入し、β−galを生産する遺伝子組換え菌
を造成した(備工研究寄第7650号)。β−gal生産
はtrpプロモータの制御下にあり、プロモータの
機能を有効に利用してβ−gal生産を向上させた。
trpプロモータを有する複合プラスミドは培養
中にIA(3−β−イドールアクリル酸)を添加す
ることにより、遺伝子が発現することが知られて
いる(Nature、vol.291、503〜506頁、1981)。
これは遺伝子の転写を抑制するリプレツサがIA
により不活性化されるため、RNAポリメラーゼ
によるmRNAの合成が開始されるからである。
本発明者らはβ−galを生産する遺伝子組換え
菌を用いてβ−galを効率よく生産させるため、
培養制御方法について種々検討し、β−galを大
量に生産させることに成功し、本発明を完成する
に至つた。
trpプロモータでは誘導物質IAを添加すればプ
ロモータが働き始めるのであるが、その添加時期
の決定が目的遺伝子産物の生産きわめて重要であ
る。IA添加時期としては上記文献のように培養
1時間目に添加する方法や菌体濃度を指標とする
方法(特開昭58−141796号公報)がある。本発明
者らはこれらの方法に対し菌体の生理活性状態に
適したIA添加を可能にするため、DO濃度変化を
指標としてIAを添加する方法を見い出した。撹
拌回転数と通気量を一定として培養する菌体の増
殖にしたがい、DO濃度が低下し、それにともな
い基質のグルコース濃度も菌による消費に低下す
る。つぎに、基質が消費された時点で急激にDO
が上昇する。この時点でIAとβ−galの合成材料
となる栄養物質を同時に添加することにより、β
−galを大量に生産させるのである。つまり、基
質の消費による菌体増殖が停止した時点でIAと
栄養物質を添加することにより、最大の菌体濃度
でβ−gal生産を開始させることができるのであ
る。
本発明における最適IA添加量は第2図に示す
ように15μg/mlであつた。これから、15μg/
ml程度IAを培養中に添加すれば良いと考えられ
る。また、IAと同時に添加する栄養物質は第1
表に示すようにカザミノ酸が効果的であり、グル
コースではβ−galの生産は低下した。カザミノ
酸はアミノ酸の混合物であるから、トリプトフア
ン以外のアミノ酸またはそれらの混合物を添加し
ても同様な結果が得られる。カザミノ酸の添加量
は多い方が生産量は向上するが、培養時間は長く
する必要がある。
[Field of Application of the Invention] The present invention relates to a method for efficiently culturing microorganisms into which a gene of interest obtained from animals, plants, microorganisms, etc. has been introduced, and producing a gene product of interest in large quantities. [Background of the Invention] It is known that genes of certain complex plasmids are expressed by adding an inducer during culture. For example, "Nature" vol.291, 503
See page 506, 11 June 1981. Recently, genetic recombination technology has been developed that uses a host microorganism that carries a complex plasmid in which a gene having production information for a useful substance has been integrated into the vector plasmid of the host microorganism, and allows the microorganism to mass-produce the above-mentioned useful substances. Human interferon, insulin, etc. are already being produced using this technology, and Escherichia coli is being used as a host microorganism. However, a method for industrially producing a desired product in large quantities using genetically modified bacteria carrying the target gene has not yet been developed, and there is an urgent need to develop efficient cultivation methods for genetically modified bacteria. There is. [Object of the Invention] An object of the present invention is to provide an efficient method for culturing genetically modified bacteria. [Summary of the Invention] The present invention involves culturing a microorganism that maintains in its cells a complex plasmid consisting of a target gene, a vector, and a promoter, and has the ability to express the target gene.
When expressing the target gene and collecting its products, the change in dissolved oxygen (DO) concentration during culture is used as an indicator, and an inducer and a nutrient are added at the same time. In the present invention, as a specific example showing the culture control method,
The trp promoter is used as a promoter, and β-
A culture control method using E. coli carrying a complex plasmid in which gal (β-galactosidase) gene is linked is shown. Figure 1 shows the structure of the composite plasmid pTREZ1 in which the trp promoter and β-gal gene are linked. trp
The promoter part is the promoter of the E. coli trp operon, and includes a portion of the tip of trpL (soda peptide) and trpE (anthranilate synthase).
It is a DNA fragment of 500bp (base pairs),
This was inserted into the EcoRI site of the pBR322 plasmid. On the other hand, the β-gal gene is expressed in pMC1403 (J.Ba-
cteriol.vol.143, pp. 971-980, 1980), with a size of 6.2 kb, which contains the trp promoter.
It was inserted between the EcoRI site and the SalI site of pBR322. The composite plasmid pTREZ1 with the structure described above was transferred to E. coli M182, a strain lacking the β-gal gene on the chromosome.
A genetically modified bacterium that produces β-gal was created by introducing it into a strain (Biko Kenkyuken No. 7650). β-gal production is under the control of the trp promoter, and the function of the promoter was effectively used to improve β-gal production. It is known that the gene of a complex plasmid with a trp promoter is expressed by adding IA (3-β-idole acrylic acid) during culture (Nature, vol. 291, pp. 503-506, 1981 ).
This is because the repressor that suppresses gene transcription is IA.
This is because mRNA synthesis by RNA polymerase is initiated. In order to efficiently produce β-gal using a genetically modified bacterium that produces β-gal, the present inventors
After various studies on culture control methods, the inventors succeeded in producing large amounts of β-gal and completed the present invention. The trp promoter starts working when the inducer IA is added, and determining the timing of its addition is extremely important for producing the target gene product. As for the timing of IA addition, there are a method of adding IA at the first hour of culture as described in the above-mentioned literature, and a method of using the bacterial cell concentration as an index (Japanese Patent Application Laid-open No. 141796/1983). The present inventors have discovered a method of adding IA using changes in DO concentration as an indicator, in order to enable addition of IA suitable for the physiologically active state of bacterial cells in contrast to these methods. As the bacteria grow while keeping the stirring speed and aeration constant, the DO concentration decreases, and the substrate glucose concentration also decreases due to consumption by the bacteria. Next, when the substrate is consumed, the DO
rises. At this point, by simultaneously adding nutrients that serve as synthesis materials for IA and β-gal, β-gal can be synthesized.
-gal is produced in large quantities. In other words, by adding IA and nutrients when bacterial cell growth due to substrate consumption has stopped, β-gal production can be started at the maximum bacterial cell concentration. The optimal amount of IA added in the present invention was 15 μg/ml as shown in FIG. From now on, 15μg/
It is considered that it is sufficient to add about ml of IA during culture. In addition, nutritional substances added at the same time as IA should be added first.
As shown in the table, casamino acids were effective, and glucose decreased the production of β-gal. Since casamino acids are a mixture of amino acids, similar results can be obtained by adding amino acids other than tryptophan or mixtures thereof. The larger the amount of casamino acid added, the higher the production amount, but the culture time needs to be longer.
つぎに本発明の実施例について具体的に説明す
るが、本発明はこれによりなんら限定されるもの
ではない。
実施例 1
菌体:複合プラスミドpTREZ1を保持する大
腸菌M182株。
培地:M9−カザミノ酸培地、組成はNH4Cl1
g、Na2HPO46g、KH2PO43g、NaCl5g、
MgSO4・7H2O0.1g、CaCl2・2H2O15mg、グル
コース5g、カザミノ酸2.5g、蒸留水1、PH
7.0である。なお、本培地には複合プラスミドを
保持する大腸菌のみを増殖させるため、アンピシ
リン(Ap)を50μg/ml添加した。
培養条件:複合プラスミドを保持する大腸菌を
100mlのM9−カザミノ酸培地を入れた500ml容振
とうフラスコ20本に接種し、振とう培養機によ
り、振幅7cm、振とう115回/min、37℃で一晩
培養した。この培養菌体を遠心分離により回収
し、50mlのM9−カザミノ酸培地に懸濁した。こ
れを種菌として2の−9−カザミノ酸培地の入
つた5ジヤーフアーメンタに接種して培養を開
始した。この際消泡剤としてレオコン1705W(ラ
イオン製)を2滴添加した。培養は温度37℃、PH
7.2、撹拌機回転数800rpm、通気量2/minで
6時間実施した。
結果:第4図に示すように、培養1.5時間目項
にDO濃度が急激に上昇したので、IAとカザミノ
酸をそれぞれ15μg/ml、2.5mg/ml添加した。
IAとカザミノ酸添加時のβ−gal生産量は
16.6U/mlであつたが、培養6時間目には1.3倍の
21.8U/mlに向上した。IAとカザミノ酸添加後は
菌体濃度はほとんど増加せず、添加したカザミノ
酸の大部分はβ−gal生産のために消費されたと
考えられる。
以上の結果から、DO濃度を指標としてIAとカ
ザミノ酸を添加することにより、β−gal生産量
を大幅に向上できることが明らかになつた。
即ち、第4図に示す本発明の実施例でDOの急
増を、DOの上昇していることと所定値以上であ
ること、或いはDOの増加の変化分が所定値以上
であることから容易に検出できるのである。
実施例 2
菌株:実施例1と同様。
培地:実施例1と同様。
培養条件:DO濃度上昇時にカザミノ酸を2.5
mg/ml添加した以外は実施例1と同様。
結果:第5図に示すように、培養1.5時間目項
にDO濃度が急激に上昇したので、カザミノ酸を
2.5mg/ml添加した。この場合、β−gal生産量及
び菌体濃度はカザミノ酸添加後ほとんど増加しな
かつた。このことから、β−gal生産向上にはIA
の添加が必要であることが分つた。
〔発明の効果〕
以上説明したように、本発明の培養制御方法に
よれば目的遺伝子を効率よく生産することができ
る。
Next, examples of the present invention will be specifically described, but the present invention is not limited thereto. Example 1 Bacterial cell: Escherichia coli M182 strain harboring complex plasmid pTREZ1. Medium: M9-casamino acid medium, composition is NH 4 Cl1
g, Na2HPO46g , KH2PO43g , NaCl5g ,
MgSO 4・7H 2 O 0.1 g, CaCl 2・2H 2 O 15 mg, glucose 5 g, casamino acid 2.5 g, distilled water 1, PH
It is 7.0. Note that ampicillin (Ap) was added at 50 μg/ml to this medium in order to proliferate only E. coli carrying the complex plasmid. Culture conditions: E. coli carrying complex plasmid
The mixture was inoculated into 20 500 ml shaking flasks containing 100 ml of M9-casamino acid medium, and cultured overnight at 37°C using a shaking incubator at an amplitude of 7 cm and shaking 115 times/min. The cultured cells were collected by centrifugation and suspended in 50 ml of M9-casamino acid medium. This was used as a seed and inoculated into a 5-jar fermenter containing 2-9-casamino acid medium to start culturing. At this time, two drops of Leocon 1705W (manufactured by Lion) were added as an antifoaming agent. Culture at 37℃ and PH
7.2, the rotation speed of the stirrer was 800 rpm, and the aeration rate was 2/min for 6 hours. Results: As shown in FIG. 4, the DO concentration rapidly increased after 1.5 hours of culture, so IA and casamino acids were added at 15 μg/ml and 2.5 mg/ml, respectively.
β-gal production when IA and casamino acids are added is
The concentration was 16.6U/ml, but at the 6th hour of culture, the concentration was 1.3 times higher.
It improved to 21.8U/ml. After the addition of IA and casamino acids, the bacterial cell concentration hardly increased, and it is thought that most of the added casamino acids were consumed for β-gal production. The above results revealed that β-gal production can be significantly improved by adding IA and casamino acids using DO concentration as an indicator. That is, in the embodiment of the present invention shown in FIG. 4, a sudden increase in DO can be easily detected because DO is rising and is above a predetermined value, or because the amount of change in increase in DO is above a predetermined value. It can be detected. Example 2 Strain: Same as Example 1. Medium: Same as Example 1. Culture conditions: 2.5 casamino acids when DO concentration increases
Same as Example 1 except that mg/ml was added. Results: As shown in Figure 5, the DO concentration rapidly increased at 1.5 hours of culture, so casamino acids were added.
2.5 mg/ml was added. In this case, the β-gal production amount and bacterial cell concentration hardly increased after the addition of casamino acids. Therefore, IA is necessary to improve β-gal production.
It was found that the addition of [Effects of the Invention] As explained above, according to the culture control method of the present invention, a target gene can be efficiently produced.
第1図は複合プラスミドpTREZ1の構造図、
第2図はIAの添加量とβ−gal生産量の関係を表
わす特性図、第3図は本発明の培養装置例の概略
図、第4図はDO濃度を指標としたIAとカザミノ
酸の添加実験を表わす特性図、第5図はDO濃度
を指標としたカザミノ酸の添加実験を表わす特性
図である。
1……培養槽、2……撹拌機、3……制御用電
子計算機、4……基質槽、5……添加槽、6,7
……定量ポンプ、8,8……導管、10……溶存
酸素計、11……溶存酸素センサ、12,13…
…導管。
Figure 1 is a structural diagram of the composite plasmid pTREZ1.
Figure 2 is a characteristic diagram showing the relationship between the amount of IA added and the amount of β-gal produced, Figure 3 is a schematic diagram of an example of the culture device of the present invention, and Figure 4 is a diagram showing the relationship between IA and casamino acids using DO concentration as an index. FIG. 5 is a characteristic diagram showing the addition experiment of casamino acid using DO concentration as an index. 1... Culture tank, 2... Stirrer, 3... Control electronic computer, 4... Substrate tank, 5... Addition tank, 6, 7
... Metering pump, 8, 8 ... Conduit, 10 ... Dissolved oxygen meter, 11 ... Dissolved oxygen sensor, 12, 13 ...
…conduit.
Claims (1)
なる複合プラスミドを細胞内に保持し、且つ目的
遺伝子の発現能を有する微生物を培養し、目的遺
伝子を発現させその生産物を採取する方法におい
て、培養中の培養液の溶存酸素濃度変化を指標と
し、前記溶存酸素濃度が急増したとき、誘導物質
と栄養物質とをほぼ同時に添加することを特徴と
する遺伝子組換え菌の培養制御方法。 2 特許請求の範囲第1項において、前記プロモ
ータがtrp(トリプトフアン)プロモータであるこ
とを特徴とする遺伝子組換え菌の培養制御方法。 3 特許請求の範囲第1項において、前記誘導物
質がIA(3−β−インドールアクリル酸)である
ことを特徴とする遺伝子組換え菌の培養制御方
法。 4 特許請求の範囲第1項において、前記栄養物
質がカザミノ酸であることを特徴とする遺伝子組
換え菌の培養制御方法。 5 特許請求の範囲第1項において、前記複合プ
ラスミドを保持する微生物が大腸菌
(Escherichia coli)であることを特徴とする遺
伝子組換え菌の培養制御方法。[Scope of Claims] 1. A method for retaining a complex plasmid consisting of a target gene, a vector, and a promoter in cells, culturing a microorganism capable of expressing the target gene, expressing the target gene, and collecting the product. . A method for controlling the culture of genetically modified bacteria, characterized in that a change in dissolved oxygen concentration of a culture solution during culture is used as an indicator, and when the dissolved oxygen concentration increases rapidly, an inducer and a nutrient are added almost simultaneously. 2. The method for controlling the culture of genetically modified bacteria according to claim 1, wherein the promoter is a trp (tryptophan) promoter. 3. A method for controlling the culture of genetically modified bacteria according to claim 1, wherein the inducer is IA (3-β-indoleacrylic acid). 4. The method for controlling the culture of genetically modified bacteria according to claim 1, wherein the nutritional substance is casamino acid. 5. The method for controlling the culture of a genetically modified bacterium according to claim 1, wherein the microorganism carrying the complex plasmid is Escherichia coli.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59191603A JPS6170982A (en) | 1984-09-14 | 1984-09-14 | Culture control method for genetically modified bacteria |
| DE8585107678T DE3585176D1 (en) | 1984-06-22 | 1985-06-21 | METHOD FOR CONTROLLING THE BREEDING OF RECOMBINANTS. |
| EP85107678A EP0165613B1 (en) | 1984-06-22 | 1985-06-21 | Process for controlling culture of recombinants |
| US07/205,603 US5674678A (en) | 1984-06-22 | 1988-06-02 | Process for controlling cultures of recombinants |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59191603A JPS6170982A (en) | 1984-09-14 | 1984-09-14 | Culture control method for genetically modified bacteria |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6170982A JPS6170982A (en) | 1986-04-11 |
| JPH0455671B2 true JPH0455671B2 (en) | 1992-09-04 |
Family
ID=16277381
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59191603A Granted JPS6170982A (en) | 1984-06-22 | 1984-09-14 | Culture control method for genetically modified bacteria |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6170982A (en) |
-
1984
- 1984-09-14 JP JP59191603A patent/JPS6170982A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6170982A (en) | 1986-04-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SU1694643A1 (en) | Strain of bacteria escherichia coli - a producer of l-threonine | |
| JPS63164891A (en) | Production of human tumor necrosis factor by yeast | |
| JPS61219379A (en) | Method of controlling culture and device therefor | |
| CN116904379A (en) | Gene recombination strain for high yield tetrahydropyrimidine and construction method and application thereof | |
| JP2676511B2 (en) | Culture method using acetic acid as an index and its apparatus | |
| JPH07110232B2 (en) | Method and apparatus for collecting gene product of transgenic E. coli | |
| SU974817A1 (en) | Method of producing l-treonin | |
| Nampoothiri et al. | Immobilization of Brevibacterium cells for the production of L-glutamic acid | |
| Lee et al. | Mass production of thermostable D‐hydantoinase by batch culture of recombinant Escherichia coli with a constitutive expression system | |
| CN115838713B (en) | A protease and its application in L-carnosine synthesis | |
| JPH05137585A (en) | Erythritol continuous culture method | |
| CN115895987B (en) | Recombinant strain for improving fructose chondroitin yield and construction method thereof | |
| CN113604413B (en) | A kind of recombinant bacterial strain and preparation method and application | |
| JPH05199867A (en) | New microorganism and production of d-biotin using the same | |
| CN118006645B (en) | A quaternary pyrimidine gene cluster derived from halophilic bacillus, mutants and applications | |
| CN117586999A (en) | New semi-continuous fermentation high-yield enzyme process | |
| US5674678A (en) | Process for controlling cultures of recombinants | |
| JPS6170982A (en) | Culture control method for genetically modified bacteria | |
| Park et al. | Analysis of kinetic paramers for the 3 β-indoleacrylic acid effect on trp promoter in Escherichia coli | |
| SU904325A1 (en) | Method of producing l-treonin | |
| CN120519414B (en) | A fully synthetic ketone reductase and its applications | |
| Narciandi et al. | Maximizing the expression of recombinant Kringle 1 (Streptokinase) synthesized in Escherichia coli. Influence of culture and induction conditions | |
| CN1504575A (en) | Control method for inducing T7 expression system by L-arabinose | |
| RU2731289C2 (en) | Method for constructing a biocatalyst strain based on bacteria of the genus rhodococcus, having nitrilase activity and high operational stability, recombinant strain of rhodococcus rhodochrous bacteria produced by such method, a method for synthesis of acrylic acid using this strain as a biocatalyst | |
| CN119286756A (en) | A recombinant Escherichia coli THRS-6 and a method for synthesizing L-threonine |